Perspectives
Nature Reviews Drug Discovery 4, 819-823 (October 2005) | doi:10.1038/nrd1850
Essay: The political logic of regulatory error
Daniel Carpenter1 & Michael M. Ting2 About the authors
Top of page
Abstract
Regulatory error is an issue that has come to the fore following the withdrawal of rofecoxib (Vioxx; Merck) a year ago. Here, we provide a theoretical discussion of the factors that could influence regulatory error, drawing on the Vioxx episode in particular as a possible example of error, and consider the implications for future regulatory policy.
Author affiliations
-
Daniel Carpenter is in the Department of Government, 1737 Cambridge St, CGIS N405, Harvard University, Cambridge, Massachusetts 02138, USA.
Email: dcarpenter@latte.harvard.edu -
Michael M. Ting is in the Department of Political Science, International Affairs Building, Floor 7, 420 West 118th Street, New York, New York 10027, USA.
Email: mmt2033@columbia.edu
Published online 23 September 2005
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphomaBone Marrow Transplantation Original Article
